Month: March 2020

Företagsmeddelande, insiderinformation, Helsingfors, 20 mars 2020, kl. 10.00Nexstim Abp: Ändring av kallelsen till årstämman och de förebyggande åtgärderna i samband med årstämmanNexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) har beslutat att istället för det som offentliggjordes i företagsmeddelandet den 10 mars 2020 som lokalen av årstämman, ska årstämman hållas i företagets egna lokaler i Helsingfors, Elimäenkatu 9 B, Helsingfors.Kallelsen till årstämman, ändrad genom denna företagsmeddelande, finns tillgänglig på bolagets webbsida: www.nextim.com/investors/shareholdermeetings/.På grund av den ökade risken för koronavirus, har Nextim beslutat om flera förebyggande åtgärder relaterade till årstämman för att minska risken för spridning av koronavirus. Dessa åtgärder är:Alla aktieägare uppmuntras starkt att utöva sin rösträtt...

Polarcus Limited (“Polarcus” or the “Company”) (OSE: PLCS) refers to its announcement dated 1 November 2018 regarding the award of a 3D marine seismic acquisition project offshore West Africa. The client has decided to cease operations on the project and the contract has been terminated. The client has accepted that compensation for early termination is payable in these circumstances. Polarcus is engaged in discussions for alternative project opportunities although the Company expects its vessel utilization in Q2, 2020 to be negatively impacted. ContactsHans-Peter Burlid, CFO+971 50 559 8175hp.burlid@polarcus.com About PolarcusThis information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Vilnius, March 20, 2020 (GLOBE NEWSWIRE) — In 2019, Medicinos Bankas UAB generated audited net profit of EUR 3.99 million, i.e. 64 per cent more than in 2018 (EUR 2.44 million). Medicinos Bankas Group earned EUR 3.85 million, i.e. 61 per cent more than a year ago (EUR 2.39 million).Last year, increase in revenue was observed in all areas of activity: operating income increased by 20 per cent (EUR 3.2 million) and reached EUR 19.3 million.In 2019, operating costs of the bank increased by 11 per cent or EUR 1.3 million and reached EUR 13.7 million. This increase resulted from an increase of wages and depreciation costs. Costs of impairment of loans and other financial assets decreased by EUR 0.4 million and were EUR 13.7 million.“The results were essentially affected by the increased volume of the services provided in three strategic...

Vilnius, March 20, 2020 (GLOBE NEWSWIRE) — 2019 m. UAB „Medicinos bankas“ uždirbo 3,99 mln. eurų audituoto grynojo pelno – 64 proc. daugiau nei 2018 m. (2,44 mln. eurų), Banko grupė – 3,85 mln. eurų, 61 proc. proc. daugiau nei prieš metus (2,39 mln. eurų).Pernai užfiksuotas pajamų augimas visose banko veiklos srityse – veiklos pajamos didėjo 20 proc. (3,2 mln. eurų) ir pasiekė 19,3 mln. eurų.Banko operacinės išlaidos 2019 m. padidėjo 11 proc., arba 1,3 mln. eurų, iki 13,7 mln. eurų. Jų augimą lėmė atlyginimų ir nusidėvėjimo sąnaudų padidėjimas. Paskolų ir kito finansinio turto vertės sumažėjimo išlaidos sumažėjo 0,4 mln. eurų iki 13,7 mln. eurų.„Rezultatams esminės įtakos turėjo padidėjusios teikiamų paslaugų apimtys trijose strateginėse mūsų banko veiklos srityse. Tai – smulkaus ir vidutinio verslo finansavimas, paslaugos privatiems...

QPR SOFTWARE STOCK EXCHANGE RELEASE, MARCH 20, 2020 AT 9.45 AMThe Parliament of Finland has, due to coronavirus epidemic, taken emergency powers legislation into use, and in accordance with it all public gatherings are strongly restricted at least until April 13, 2020. We take the measures to mitigate the coronavirus seriously and therefore QPR Software´s Board of Directors resolved to cancel the Annual General Meeting scheduled to be held on April 7, 2020.The Board of Directors will convene the Annual General Meeting at a later stage as soon as it is practically possible to organize the meeting. The Board of Directors will closely monitor the development of coronavirus epidemic, as well as the official codes and acts pertaining to it, and reserves the right to convene a new meeting later than the Company´s Articles of Association stipulate...

QPR SOFTWARE PÖRSSITIEDOTE 20.3.2020 KLO 9.45Suomen eduskunta on koronavirusepidemian vuoksi ottanut käyttöön valmiuslain, ja julkisia kokoontumisia rajoitetaan merkittävästi ainakin 13.4.2020 saakka. Suhtaudumme koronaviruksen torjuntaan tähtääviin toimiin vakavasti, minkä vuoksi QPR Software Oyj:n hallitus on päättänyt peruuttaa alun perin 7.4.2020 pidettäväksi ilmoitetun varsinaisen yhtiökokouksen.QPR Software Oyj:n hallitus kutsuu varsinaisen yhtiökokouksen koolle myöhemmin niin pian kuin kokouksen pitäminen on käytännössä mahdollista. Yhtiön hallitus seuraa tarkasti epidemiatilanteen kehittymistä ja viranomaisohjeistuksia sekä varaa oikeuden siirtää varsinaisen yhtiökokouksen pitoajan yhtiöjärjestyksessä määrättyä kesäkuun lopun aikarajaa pidemmällekin.QPR SOFTWARE OYJHALLITUSLisätietoja:Toimitusjohtaja Jari Jaakkola, puh. 040 5026...

Today, 20 March 2020, the Board of Directors approved the Annual Report for 2019.Please find the Annual Report, including the ESG Report (chapter 5) for 2019 attached.For further information, please contact:James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASAPhone: +41 799501034E-mail: jb@hofsethbiocare.noJon Olav Ødegård, CFO of Hofseth BioCare ASAPhone: +47 93632966E-mail: joo@hofsethbiocare.noAbout Hofseth BioCareHBC is a Norwegian biotech company that develops high-value ingredients and finished products from Norwegian salmon off-cuts. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food...

Styret i Hofseth BioCare ASA har i dag 20. mars 2020 godkjent årsrapporten for 2019.Årsrapporten inkludert ESG-rapport (kapittel 5) for 2019 ligger vedlagt.For ytterligere informasjon, vennligst kontakt:James Berger, Head of Investor Relations & Strategy i Hofseth BioCare ASAMob: +41 799501034E-post: jb@hofsethbiocare.noJon Olav Ødegård, CFO i Hofseth BioCare ASAMob: +47 93632966E-post: joo@hofsethbiocare.noOm Hofseth BioCare ASA:HBC er et norsk bioteknologiselskap som utvikler høyverdige ingredienser og ferdigprodukter av avskjær fra norsk laks. Ingredienser videreutvikles til forskning og prekliniske studier i flere klinikker og forskningslaboratorier på universiteter i flere land. Ledende kliniske og prekliniske kandidater utvikles mot gastrointestinal beskyttende medisinsk mat, medisinsk mat for å hjelpe til med å behandle aldersrelatert...

 Vow ASA today announced updates to its cruise and land-based operations in response to the Covid-19.The safety of employees and subcontractors is a top priority for Vow. The company is pleased to confirm that its employees are safe and healthy and that its business is continuing mostly uninterrupted. “We are particularly impressed with how our customers in the cruise industry have responded to the global call for action, docking many of their ships to slow down the spread of Covid-19. At the same time, they continue to be committed to their pledge to offer even more sophisticated, climate and environmentally friendly cruise experiences in the future,” says Henrik Badin, CEO of Vow ASA.For Vow this means that all existing newbuild projects are continuing with only minimal adjustments in the plans. The shipyards ask for reassurance that...

Hørsholm, Denmark (20 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that it has received feedback from its recent pre-NDA meeting with the U.S. FDA regarding a potential path to approval for Dovitinib, one of its top priority programs.The Company attended a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential path to approval for Dovitinib used to treat Renal Cell Carcinoma (RCC) (kidney cancer), the current lead indication for the drug. The Company’s proposal is to seek approval based on “non-inferiority” against the already approved compound Sorafenib (Bayer), based on prior Phase 3 trial results (by Novartis).  In the pre-NDA meeting and the subsequent Meeting Memorandum, the FDA indicated that they would accept the NDA filing if submitted, and provided additional guidance...